Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tristan Lai

Interventional Pain Medicine Spring Branch, TX Medical Doctor

NPI 1699976217 CMS profile 303521

19750 State Highway 46 W Ste 104, Ste 104, Spring Branch, TX 78070

Open in the dashboard

General payments

$23,966

440 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tristan Lai of Spring Branch, TX is reported in the CMS Open Payments database as having received $23,966 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,672 53
2024 General $3,885 67
2023 General $2,343 50
2022 General $4,405 119
2021 General $2,230 68
2020 General $1,337 48
2019 General $1,096 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tristan Lai
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Tristan Lai were reported at $8,672. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Tristan Lai Interventional Pain Medicine median Middle half National median
2019 $1,096 $684 $216–$2,079 $163
2020 $1,337 $382 $122–$1,109 $114
2021 $2,230 $552 $167–$1,554 $132
2022 $4,405 $605 $187–$1,924 $149
2023 $2,343 $671 $195–$1,915 $160
2024 $3,885 $684 $206–$1,837 $164
2025 $8,672 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,845 250 payments
  2. Boston Scientific Corporation $2,678 34 payments
  3. Medtronic, Inc. $2,170 50 payments
  4. Relievant Medsystems, Inc. $503 3 payments
  5. SI-BONE, Inc. $400 10 payments
  6. Saluda Medical Americas, Inc. $362 4 payments
  7. Nevro Corp. $338 8 payments
  8. Medtronic USA, Inc. $207 12 payments
  9. Collegium Pharmaceutical, Inc. $167 11 payments
  10. AbbVie, Inc. $165 6 payments
  11. Other $1,132 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,470 424 payments
  2. Consulting Fee $6,800 5 payments
  3. Travel and Lodging $2,696 11 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Structural Heart $5,985 9 payments
  2. PROCLAIM Neuromodulation $3,193 75 payments
  3. SYNCHROMEDII $1,842 33 payments
  4. Intracept Pain $1,168 10 payments
  5. Proclaim Family of SCS IPGs $1,114 35 payments
  6. Intracept Intracept Drill_NMOD $668 3 payments
  7. Prodigy Family of SCS IPGs $660 9 payments
  8. ETERNA $548 14 payments
  9. Proclaim IPG $508 28 payments
  10. Intracept Pain $488 2 payments
  11. Other $8,831 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,909

Median for Anesthesiology: 322

Drug cost

$147,854

Median for Anesthesiology: $8,738

Branded share of claims

40.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 55 $32,154
Buprenorphine Generic 108 $27,839
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 834 $27,421
Oxycontin Oxycodone Hcl Brand 17 $9,292
Celecoxib Generic 219 $9,156
Hysingla Er Hydrocodone Bitartrate Brand 17 $5,663
Tizanidine Hcl Generic 243 $5,401
Gabapentin Generic 257 $4,291
Lidocaine Generic 28 $3,372
Pregabalin Generic 111 $3,233

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$282,459

Of which drugs: $12,263

Medicare patients

325

Average age 72

Services billed

12,480

176 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 29%
Ischemic heart disease 28%
Diabetes 25%
Chronic kidney disease 22%
Atrial fibrillation 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 102 6,039 $1,720
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 44 1,211 $272
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 27 27 $120
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 162 $114
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 48 641 $58
Injection, midazolam hydrochloride, per 1 mg J2250 Office 25 143 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $62
$62 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $33
$33 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $29
$29 55 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record